View More View Less
  • 1 Dél-pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, Budapest, Albert Flórián út 5–7., 1097
  • 2 Dél-pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, Budapest
  • 3 Dél-pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, Budapest
  • 4 Dél-pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, Budapest
  • 5 Dél-pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, Budapest
Open access

Absztrakt:

Az elmúlt hónapokban pandémiához vezető, Kínából induló, új koronavírus okozta megbetegedés (COVID–19) rámutatott az emberiség kiszolgáltatottságára. Aktuálisan a COVID–19 kezelésére randomizált kontrollált vizsgálattal igazolt hatékonyságú, törzskönyvezett gyógyszer nem áll rendelkezésre. A súlyos akut légúti tünetegyüttest okozó koronavírus-2 (SARS-CoV-2) a jelen munka írásáig – a legóvatosabb becslések szerint is – közel 4 millió fertőzésért és megközelítőleg 300 000 halálesetért felelős. A patomechanizmus mélyebb megismerése fedte fel, hogy a fatális esetek hátterében az immunválasz diszregulációja, a citokinvihar-szindróma (CRS) áll. Eddigi ismereteink alapján a COVID–19-ben kialakuló citokinvihar sarkalatos szereplője az interleukin-6 (IL6). Esetleírások és kis betegcsoportokon végzett vizsgálatok eredményei alapján az IL6 monoklonális antitest gátló terápia (tocilizumab) eredményesnek mutatkozik a citokinvihar kezelésében. A szerzők egy eset leírása kapcsán foglalják össze a legfrissebb ismereteket a COVID–19 terápiájával kapcsolatosan. A jelen esetismertetés súlyos COVID–19-ben szenvedő betegben kialakult CRS sikeres terápiáját mutatja be, melynek során – a szerzők tudomása szerint – hazánkban elsőként került sor tocilizumab alkalmazására infektológiai osztályon. Orv Hetil. 2020; 161(26): 1070–1077.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239–1242.

  • 2

    Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020 Apr 22. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 3

    Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020; 20: 269–270.

  • 4

    Szekanecz Z, Bálint P, Balog A, et al. Immunologic and rheumatologic aspects of COVID-19. [A COVID–19 immunológiai és reumatológiai vonatkozásai.] Immunol Szle. 2020 Apr 24. [Epub ahead of print] [Hungarian]

  • 5

    Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020; 55(5): 105954.

  • 6

    Michot JM, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol. 2020 Mar 27. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 7

    Fábián Á, László I, Juhász M, et al. Pharmacological options in treating SARS-CoV-2 infection/COVID-19. [Farmakoterápiás lehetőségek SARS-CoV-2-fertőzés/COVID–19-betegség esetén.] Orv Hetil. 2020; 161: 685–688. [Hungarian]

  • 8

    Váradi A, Ferenczi T, Falus A. The coronavirus-induced COVID-19 pandemic. Previous experiences and scientific evidences at the end of March, 2020. [A koronavírus okozta COVID–19-pandémia. Korábbi tapasztalatok és tudományos evidenciák 2020. március végén.] Orv Hetil. 2020; 161: 644–651. [Hungarian]

  • 9

    Saglietto A, D’Ascenzo F, Zoccai GB, et al. COVID-19 in Europe: the Italian lesson. Lancet 2020; 395: 1110–1111.

  • 10

    Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020; 38: 379–381.

  • 11

    Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14: 58–60.

  • 12

    Patrì A, Fabbrocini G. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment? J Am Acad Dermatol. 2020 Apr 10. Doi: 10.1016/j.jaad.2020.04.017 [Epub ahead of print]

  • 13

    Sanders JM, Monogue ML, Jodlowski T, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 2020 Apr 13. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 14

    Fedson DS, Opal SM, Rordam OM. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. mBio 2020; 11: e00398-20.

  • 15

    Bavel JJ, Baicker K, Boggio PS, et al. Using social and behavioural science to support COVID-19 pandemic response. Nat Hum Behav. 2020 Apr 30. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 16

    Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003; 3: 722–727.

  • 17

    Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6: 16. .

    • Crossref
    • Export Citation
  • 18

    Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 19

    Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14: 72–73.

  • 20

    Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 Mar 20. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 21

    Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020. 03. 22. https://doi.org/10.1101/2020.03.22.20040758. [Epub ahead of print]

  • 22

    Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. medRxiv 2020. 04. 10. https://doi.org/10.1101/2020.04.10.20060558. [Epub ahead of print]

  • 23

    Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020 Mar 10. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 24

    Intson K. Kumar SA, Botta A, et al. An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19. Swiss Med Wkly. 2020; 150: w20262.

  • 25

    Borba MG, Val FF, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open 2020; 3: e208857.

  • 26

    Perinel S, Launay M, Botelho-Nevers E, et al. Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients. Clin Infect Dis. 2020 Apr 7. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 27

    Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). 2020; 49: 215–219.

  • 28

    Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020 Mar 30. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 29

    Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med. 2020 Apr 15. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 30

    Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020 Apr 27. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 31

    Yazdany J, Kim AH. Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. Ann Intern Med. 2020 Mar 31. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 32

    Mercuro NJ, Yen CF, Shim DJ. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 May 1. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 33

    Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020; 382: 1787–1799.

  • 34

    University of Liverpool. COVID-19 drug interactions. Available from: https://www.covid19-druginteractions.org/ [accessed: April 28, 2020].

  • 35

    Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020 Apr 10. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 36

    Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020 Apr 29. https://doi.org/10.1016/S0140-6736(20)31022-9. [Epub ahead of print]

  • 37

    Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020 Mar 18. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 38

    Chen Ch, Zhang Y, Huang J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv 2020. 03. 17. Doi: https://doi.org/10.1101/2020.03.17.20037432.

  • 39

    Jin Y, Yang H, Ji W. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020; 12: E372.

  • 40

    Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020; 27: 1451–1454.

  • 41

    Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033–1034.

  • 42

    Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014; 66: 2613–2620.

  • 43

    Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVID-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 2020; 34: 1. .

    • Crossref
    • Export Citation
  • 44

    Coomes E, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. medRxiv 2020. 04. 03. .

    • Crossref
    • Export Citation
  • 45

    Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020; 4: 1307–1310.

  • 46

    Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020 Apr 6. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 47

    Alzghari SK, Acuña VS. Supportive treatment with tocilizumab for COVID-19: a systematic review. J Clin Virol. 2020 Apr 21. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 48

    Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020 Apr 29. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 49

    Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol. 2020 May 1. PMID: 32359035. [Epub ahead of print]

  • 50

    Liu B, Li M, Zhou Z, et al. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020 Apr 10. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 51

    Yuen KS, Ye ZW, Fung SY, et al. SARS-CoV-2 and COVID-19: the most important research questions. Cell Biosci. 2020; 10: 40.

The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.

Mendeley citation style is available HERE.

 

MANUSCRIPT SUBMISSION

  • Impact Factor (2018): 0.564
  • Medicine (miscellaneous) SJR Quartile Score (2018): Q3
  • Scimago Journal Rank (2018): 0.193
  • SJR Hirsch-Index (2018): 18

Language: Hungarian

Founded in 1857
Publication: Weekly, one volume of 52 issues annually

Senior editors

Editor(s)-in-Chief: Papp Zoltán

Read the professional career of Papp Zoltán HERE.

 

Editorial Board

Click for the Editorial Board

Akadémiai Kiadó
Address: Prielle Kornélia u. 21-35. H-1117 Budapest, Hungary
Phone: (+36 1) 464 8235 ---- Fax: (+36 1) 464 8221
Email: orvosihetilap@akkrt.hu